Celescreen was created in 2015 to develop a toxicity screening technology invented by Pr. Philippe Manivet, the leader of biobanking activities at Hôpital Lariboisière. This innovative and patented method implements the well-known C. elegans to evaluate the toxicity of any xenobiotic molecule, the unicity of the method relying in a special cargo vehicle overcoming the poor appetite of C. elegans for many xenobiotics. The primary business target of Celescreen has been the cosmetics industry wherein testing on vertebrate animals is now strictly forbidden jeopardizing innovation in the whole industry. Celescreen is now expanding its focus towards medical research, pharmaceutical development and endocrine disruptors.
Health, Welfare, Biotechnologies and Industry